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The Conradi±HuÈnermann±Happle syndrome is an
X-linked dominant disease that is due to mutations
in the gene for emopamil binding protein.
Emopamil binding protein is a D8±D7 sterol isomer-
ase and plays a pivotal role in the ®nal steps of
cholesterol biosynthesis. We wanted to know to what
extent this X-linked dominant enzyme defect has
functional consequences at the biochemical level
and whether it is possible to predict the clinical
phenotype from serum sterol measurements.
Therefore we performed sterol biochemical studies
in 11 Conradi±HuÈnermann±Happle syndrome fam-
ilies and compared the results obtained to the clinical
and molecular genetic ®ndings. To assess disease
severity a score considering bone and skin involve-
ment and further features was used. For evaluation
of the functional consequences we studied serum
samples using gas chromatography-mass spectrome-
try analysis. For mutation screening we analyzed the
emopamil binding protein gene using polymerase
chain reaction, heteroduplex analysis of all exons,
direct sequencing, and restriction enzyme analysis.
Mutations in the emopamil binding protein gene
were found in all 11 families including seven novel
mutations affecting exons 2, 4, and 5. Gas chromato-
graphy±mass spectrometry analysis revealed mark-
edly elevated levels of 8-dehydrocholesterol and of
cholest-8(9)-en-3b-ol and helped to identify somatic
mosaicism in a clinically unaffected man. The extent
of the metabolic alterations in the serum, however,
do not allow prediction of the clinical phenotype,
nor the genotype. This lack of correlation may be
due to differences in X-inactivation between differ-
ent tissues of the same patient and/or loss of the
mutant clone by outgrowth of pro®cient clones after
some time. Key words: cholesterol/ichthyosis/somatic
mosaicism/sterol isomerase/X-chromosomal dominant chon-
drodysplasia punctata. J Invest Dermatol 118:851±858,
2002
T
he Conradi±HuÈnermann±Happle (CHH) syndrome
(MIM#302960) is an X-chromosomal dominant
disorder that usually affects only females and is lethal
in males. Mutations in the gene encoding the
emopamil binding protein have been reported
(Braverman et al, 1999; Derry et al, 1999). The emopamil binding
protein is located mainly in the membrane of the endoplasmatic
reticulum, having four functionally important transmembrane
domains. Although it was ®rst described as a receptor for emopamil
and other anti-ischemic drugs, the main role of emopamil binding
protein is its function as an enzyme in the cholesterol biosynthesis
pathway, converting cholest-8(9)-en-3b-ol (cholestenol) into
cholest-7-en-3b-ol (lathosterol) and thus acting as a D8±D7 sterol
isomerase (Silve et al, 1996).
The clinical phenotype of the CHH syndrome is variable,
ranging from stillborn or lethal forms to mild, almost clinically
undetectable forms. The clinical hallmarks of the CHH syndrome
are linear ichthyosis, chondrodysplasia punctata, asymmetrically
shortened limbs, unilateral, sometimes sectorial, cataracts, and short
stature (Happle, 1977; Traupe et al, 1992). The asymmetry of the
disease manifestations within a patient (limbs and cataracts) has been
explained by differences in X-chromosome inactivation (lyoniza-
tion) (Happle, 1985; Traupe, 1999).
For an X-linked dominant gene defect one would expect in
heterozygous females only a partial biochemical de®ciency as
roughly 50% of all cells should express the enzyme, which should
be suf®cient for cholesterol biosynthesis. We therefore wanted to
know to what extent the D8±D7 sterol isomerase de®ciency has
obvious functional consequences in the CHH syndrome, as
suggested in previous investigations (Braverman et al, 1999;
Kelley et al, 1999), and whether there is a clear-cut relationship
between biochemical phenotype and genotype. To address these
two questions we performed sterol biochemical studies using gas
chromatography±mass spectrometry (GC-MS) and compared the
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results obtained with the clinical and molecular ®ndings in 11
families.
MATERIALS AND METHODS
Family study We studied 11 families with CHH syndrome,
comprising 31 individuals altogether. Family members were examined by
experienced clinicians ± two dermatologists (HT and EF) and a specialist
in pediatrics and medical genetics (IB). The clinical diagnosis of CHH
syndrome was established in 14 females. Mutations in three of the 11
families have been previously reported by us, family 1 corresponding to
family 4, 2 to family 5, and family 5 to family 6 of our earlier study (Has
et al, 2000). We developed a clinical score to assess the severity of the
disease in our patients. In short, we evaluated in each patient the
following features: (i) hyperkeratosis, re¯ecting the actual activity of skin
disease: 0, absent; 1, small patches; 2, large areas; 3, severe generalized
ichthyosis; (ii) skeletal abnormalities: 0, absent; 1, asymmetric shortening
of one or two limbs; 2, asymmetric shortening of one or two limbs and/
or vertebral change and/or hip dislocation; 3, severe orthopedic
handicap; (iii) eyes: 0, no clinical impairment; 1, severe cataract with
visual impairment; (iv) cicatricial alopecia: 0, absent; 1, present; (v)
concomitant diseases are listed when applicable, not considered for the
scoring; (vi) fatal outcome when related to disease: 0, absent; 1, present.
GC-MS studies Serum samples from the patients and their parents
were collected and analyzed by GC-MS to determine the levels of
cholesterol and of the following cholesterol precursors: 8-
dehydrocholesterol (8-DHC), cholest-8(9)-en-3b-ol (cholestenol),
desmosterol, and lathosterol.
Organic solvents and water were of high performance liquid
chromatography grade and purchased from Baker (Griesheim, Germany).
Hexane and pyridine were dried over molecular sieves (Merck,
Darmstadt, Germany, 0.4 nm). Sterol standards and all other chemicals
were of analytical grade and obtained from Sigma (Deisenhofen,
Germany).
Internal standards (10 mg epicoprostanol and 100 mg coprostanol) were
added to 100 ml of serum followed by saponi®cation with tetramethy-
lammonium hydroxide/isopropanol (400 ml, 20% wt/vol) for 15 min at
80°C. After cooling to room temperature 800 ml of water were added
and cholesterol and cholesterol precursors were extracted with tetrachlor-
oethylene (200 ml, 30 s vortex, 10 min centrifugation at 2000 3 g)
(Klansek et al, 1995). The organic fraction was evaporated and the
residue containing the sterols was derivatized into trimethylsilyl ethers
with pyridine:hexamethyldisilazane:trimethylchlorosilane (9:3:1 vol:vol:-
vol; 200 ml) at 60°C for 30 min. After removal of excess reagents the
residue was dissolved in 100 ml n-hexane:pyridine (99:1, vol:vol),
sonicated, and centrifuged at 2000 3 g for 5 min. The supernatant was
subjected to further analysis by GC-MS.
GC-MS analysis of sterols was performed on a GCQ (Thermo
Finnigan, Egelsbach, Germany) equipped with an ion trap mass analyzer
and an HT-5 fused silica capillary column (SGE, Weiterstadt, Germany;
25 m, inner diameter 0.22 mm, ®lm thickness 0.1 mm). One microliter
of the sample was injected splitless at 280°C. Helium was used as carrier
gas at a constant velocity of 30 cm per s. The temperature of the column
oven was maintained at 80°C for 1 min, increased at 25°C per min to
225°C, and ®nally increased at 2°C per min to 280°C. The parameters
for the ion trap mass analyzer were as follows: transfer line at 280°C,
positive EI mode (70 eV), ion source at 200°C, full scan on masses 50±
650 Da; AGC target value 50. Sterol compound concentrations were
quanti®ed by comparing the ion current response of the sum of
characteristic quantitation masses with the peak area response obtained
for the known amount of the added internal standards (epicoprostanol
for cholesterol precursors, coprostanol for cholesterol).
DNA studies DNA was isolated from ethylenediamine tetraacetic acid
(EDTA) blood samples using the QIAamp Blood minikit (Qiagen,
Hiltrup, Germany). For the parents of the probands 1 and 2, we also
extracted DNA from hair follicles using the same kit. We also isolated
DNA from the sperm of the father of proband 1. A hundred microliters
of sperm sample were treated with 80 ml buffer X2 (Tris±HCl 25 mM,
pH 8, EDTA 25 mM, NaCl 250 mM, dithiothreitol 100 mM, sodium
dodecyl sulfate 5%) and proteinase K (Qiagen Standard) and incubated
for 2 h at 55°C. For DNA extraction the Qiagen tissue kit was used.
The four coding exons 2, 3, 4, and 5 of the emopamil binding protein
gene were ampli®ed by polymerase chain reaction (PCR) using the
following intronic primers. For exon 2, 5¢-CTTCCTGCCTATAC-
ACACGC-3¢ (forward) and 5¢-AGCAAATCCCATCCCACAGC-3¢
(reverse); for exons 3 and 4, 5¢-GTGTGTGTTCCTTTCACTGC-3¢
(forward) and 5¢-CATCTGTGTCTGTGGATCCC-3¢ (reverse); and for
exon 5, 5¢-AAGGTGTGAGCTCTCCTGAG-3¢ (forward) and 5¢-
GACTAGACTCTTCTGGCAGG-3¢ (reverse). Cycling conditions were
as follows: 95°C for 5 min, 95°C for 45 s, 54°C for 45 s, and 72°C for
45 s for 40 cycles, and extension at 72°C for 10 min (Perkin Elmer).
Heteroduplex analysis using conformation sensitive gel electrophoresis
(CSGE) was performed in order to screen the PCR products for
mutations (Ganguly et al, 1993). PCR products showing conformation
changes were then sequenced from both directions on an automated
sequencer (ABI 310, PE Biosystems). When possible, mutations were
con®rmed by restriction enzyme analysis. For the novel mutations 150
chromosomes from normal controls were screened by CSGE.
RESULTS
Family study Figure 1 gives the pedigree of family 1. Detailed
clinical data of the index patients and further relatives are given
below (Table I).
Typical clinical ®ndings concerning skin and skeletal involve-
ment are illustrated in Fig 2(a)±(e).
GC-MS analysis The results of GC-MS, as well as the overall
clinical score and the molecular ®ndings, are summarized in
Table II. We found markedly elevated levels of 8-DHC and
cholestenol in all cases of CHH syndrome. We tested also both
parents of the index patients and sometimes further family members
and obtained normal results in the clinically unaffected relatives.
The only exception was the father of family 1. This individual was
shown to exhibit both gonadal and somatic mosaicisms as
evidenced by our molecular studies (see below). We wanted to
know whether the changes of the sterol precursors show constant
levels and therefore repeated these analyses after 6±12 mo in nine
patients. The second sample was measured twice (see Table II,
measurements II and III). No special diet was prescribed. We
observed no major ¯uctuations of the values (see Table II). The
limit of detection for 8-DHC and cholestenol was 0.5 mg per liter.
In 20 normal controls 8-DHC and cholestenol could not be
detected by GC-MS analysis (data not shown).
Desmosterol and lathosterol showed normal levels and were not
included in Table II.
Figure 3(A), (B) shows the GC-MS analysis of the mother of
family 3 and of an unaffected control.
Mutation analysis Using CSGE as a tool for mutation screening
we found conformation changes in DNA samples from all patients.
The sequencing of the PCR products revealed the following
mutations: three missense (exons 2, 4, and 5), three nonsense
(exons 2 and 4), two deletions (exon 4), one insertion, and one
splice site mutation (Table II). The mutations in families 1, 2, and
5 have already been reported by us (Has et al, 2000). In the previous
study we did not ®nd a mutation in DNA samples extracted from
lymphocytes from the parents of the proband of family 1 (family 4
in our previous report). Here we extended our analysis to include
hair follicles and sperm of the father. Heteroduplex analysis and
sequencing data showed the mutation nt440(G®A), as well as the
normal sequence in the father of family 1 in the sample extracted
Figure 1. Pedigree of family 1.
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1 German 2 1 2 0 1 0 4
1 German 17 d 3 3 0 0 1 7
1 German 33 0 0 0 0 0 0
2 German 33 2 1 1 1 0 5
3 German 21 1 1 1 1 0 4
3 German 55 0 1 0 1 0 2
4 German 37 2 3 1 1 0 7
5 Dutch 14 1 2 1 1 0 5
6 German 2 1 2 0 1 0 4
7 German 43 0 2 0 1 unilateral
aplasia of kidney; 0
3
8 German 38 3 1 1 1 severe recurrent skin
infections; death ± SSSS
1
7
9 Croatian 5 1 1 0 0 cleft of left nostril; 0 2
10 Croatian 4 1 1 0 1 syndactyly 2nd and 3rd toes
of left leg and 1st and 2nd of
right leg; 0
3
11 German 4 m 1 2 0 0 0 3



























































from hair follicles and sperm (Fig 4). The mutations 608(T®C),
451(C®T), 246(G®C), 141(G®A), nt338 + 1(G®A),
nt353(delCA), 33(C®G) (Fig 5) are novel and were not
identi®ed in 150 chromosomes from normal controls.
DISCUSSION
In agreement with two previous studies (Braverman et al, 1999;
Kelley et al, 1999) we show here that GC-MS determination of
cholesterol precursors in serum is a valuable tool in the diagnosis of
the CHH syndrome. We ®nd that in all our patients with the CHH
syndrome there is de®cient D8±D7 sterol isomerase function with
the consequence of a very marked accumulation of upstream sterol
precursors such as 8-DHC and cholestenol (see Fig 6).
The CHH syndrome belongs to a group of genetic disorders that
are due to disturbances of cholesterol biosynthesis. Other repre-
sentatives of this group are the well-studied Smith±Lemli±Opitz
(SLO) syndrome exhibiting a defect of 7-dehydrocholesterol (7-
DHC) reductase and the CHILD syndrome, in which 3b-
hydroxysteroid dehydrogenase is de®cient. For the SLO syndrome
extensive lipid chemical studies are available, whereas in the CHH
syndrome only a few studies have been performed dealing with
sterol metabolism. From the vast experience with SLO syndrome,
it can be concluded that serum sterol levels are stable and do not
vary from week to week. They are not affected by everyday diet;
Figure 2. Clinical ®ndings in the CHH
syndrome. (a) Linear hyperkeratosis following
the lines of Blaschko on the back in a neonate
(proband of family 1). (b) Large area of
hyperkeratosis on the right lower leg (proband of
family 2). (c) Asymmetric shortening of right
lower limb (same patient as in b). (d) Vertebral
changes resulting in kyphoskoliosis (proband of
family 1). (e) Cicatricial alopecia of the scalp
(proband of family 1 at the age of 2 y).
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however, after institution of strongly cholesterol-enriched diet for
several months, effects on sterol metabolism have been shown. It
should be noted that variation in sterol levels stems from differences
in genotype, age, diet, rate of growth, and other factors (Ruan et al,
2001). For example, in the SLO syndrome, the elevation of 7-
DHC ranged from 100-fold in mild cases to about 10,000-fold in a
severely affected subject (Ruan et al, 2001). In their study on 84
patients with SLO syndrome, Witsch-Baumgartner et al (2000)
found also a positive correlation between clinical severity and
elevated relative 7-DHC concentration. Cunniff et al (1997)
observed that lower serum cholesterol levels were associated with a
more severe clinical phenotype, data con®rmed by others (Yu et al,
2000).
The major clinical manifestations in CHH syndrome concern
bone and skin; however, focal mosaic expression is seen and it is
dif®cult to obtain a tissue sample that re¯ects the overall
biochemical situation. It can be assumed that the liver combined
with other peripheral tissues is the source of the elevated serum
sterols. Therefore, we, as others, decided to study the serum
samples as they best re¯ect the overall biochemical situation.
Reproducibility of serum sterol measurements using GC-MS has
been high. The SD for GC-MS analysis inclusive of sample
preparation was 620.2% for 8-DHC and 624.1% for cholestenol
(N = 10).
The issue of the extent of the biochemical alterations is
intriguing as we deal in the CHH syndrome with an X-linked









age (years) Protein level I II III I II III I II III score
1/Proband, 2 440(G®A)
R147H
14.4 4.4 4.3 14.3 4.3 4.1 1198 1627 1627 4
1/Sister N/A N/A N/A N/A 7
1/Mother ± ND ND 1759 ±
1/Father, 33 440(G®A)
R147H
3.8 2.2 1.9 3.5 3.2 2.9 1831 2189 2189 0
2/Proband, 33 nt390(delA)
frameshift
3.0 2.0 1.9 2.0 2.7 2.5 1299 1823 1823 5
2/Mother ± ND ND 1985 ±




N/A N/A N/A 4
3/Mother, 55 608(T®C)
L203P
9.5 6.4 7.1 13.3 7.8 7.9 1509 2337 2337 2




6.5 6.5 5.6 16.9 12 11.5 2308 3298 3298 7
4/Mother ± ND ND 3356 ±
5/Proband, 14 nt586(insA)
frameshift
4.5 2.1 1.9 4.9 3.2 2.7 1730 2207 2207 5
5/Mother ± ND ND 1473 ±
5/Father ± ND ND 2445 ±




1.3 1.1 1.5 4.3 0.8 1.1 491 1407 1407 4
6/Mother ± ND ND 1033 ±




2.4 8.1 1228 3
8/Proband, 38 nt338 + 1(G®A)
splice site
novel mutation
0.9 6.0 2362 7
9/Proband, 5 nt353(delCA)
novel mutation
4.6 6.5 1790 2
9/Mother ± ND ND 1502 ±
9/Father ± ND ND 2059 ±




0.9 2.7 1511 3
10/Mother ± ND ND 1348 ±





3.0 1.2 1.4 5.2 2.9 2.7 1023 1654 1654 3
11/Mother, 34 440(G®A)
R147H
0.7 2.4 1.6 3.0 2.7 2.6 918 1209 1209 7
11/Father ± ND ND 1745 ±
aI, II, and III represent the ®rst, the second and the third measurement. N/A, samples not available. ND, not detectable.
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enzyme defect. A priori one would assume that, due to random X-
inactivation, about 50% of all cells should have D8±D7 sterol
isomerase activity, which should be suf®cient to compensate such a
partial enzyme de®ciency. Our ®nding and that of Kelley et al
(1999) of markedly elevated 8-DHC and cholestenol values in the
serum lead to the conclusion that individual cell clones are unable
to convert the sterol metabolites at the single cell level and that this
task apparently cannot be taken over by those neighboring cell
clones in which the wild-type allele is active.
We report seven novel mutations in the emopamil binding
protein gene in patients with CHH syndrome: 608(T®C),
451(C®T), 246(G®C), 141(G®A), nt338 + 1(G®A),
nt353(delCA), 33(C®G), affecting exons 2, 4, 5, and intron 3.
Three mutations had already been described by us (Has et al, 2000).
The marked accumulation of cholesterol precursors in serum in the
cases having novel mutations demonstrates that these mutations are
functionally relevant.
In family 1 there was clinical evidence of germline mosaicism in
the parent generation, because the disease showed recurrence
affecting two daughters. Neither in the mother nor in the father
were there clinical ®ndings of CHH syndrome. Surprisingly we did
not ®nd the mutation in the mother, but we did in the father in
DNA extracted from hair follicles and also from sperm. By GC-MS
analysis, we could demonstrate an accumulation of 8-DHC and
cholestenol in the serum of this man. We therefore conclude that
he has a gonadal and somatic mosaic for this mutation. There are
few reports in the literature concerning males affected by CHH
syndrome (Crovato and Rebora, 1985; De Raeve et al, 1989;
Tronnier et al, 1992; Sutphen et al, 1995; Sillevis Smitt and
Jansweijer, 19871), all of them reporting rather severe clinical
®ndings. Somatic mosaicism in the CHH syndrome has previously
been noted in a male patient by Metzenberg et al (1999).2
The mutation in family 2 seems to be de novo, affecting only the
proband. In family 3 the mutation was found in the proband and
her mother, both showing clinical evidence of the disease. The
deceased grandmother was also considered to be affected as she had
cutaneous and skeletal ®ndings of the CHH syndrome. In this
family the mutation concerns leucin 203, which is a conserved
amino acid in the transmembrane domain 4 of emopamil binding
protein. In family 4, the proband has a de novo mutation, which
converts the codon for glutamin 151 into a stop codon. In all the
other families except the last, mutations are de novo (only one family
member being affected, without signi®cant history). Tryptophane
47 and 82 are located in the transmembrane domains 2 and 3. The
intronic substitution found in family 8 affects the splice site
between exon 3 and intron 3. R147H seems to be a frequent
mutation, already described in patients having an American and
Japanese background (Braverman et al, 1999; Ikegawa et al, 2000).
In family 1 we show that this mutation occurred de novo in the
father and therefore is unrelated to the mutation in family 11.
Whereas Ikegawa et al (2000) suggested that phenotypes of the
individuals with missense mutations do not always result in a full-
blown disease of CHH syndrome, our experience is otherwise. We
®nd patients with R147H have variable clinical pictures, including
very severe bone abnormalities (see deceased sister in family 1 and
severely affected mother in family 11). Nonsense and frameshift
mutations seem to prevail in the CHH syndrome and were present
in 10 of 14 families studied by us comprising our previously
reported families, whereas missense mutations were identi®ed only
in four patients.
Although determination of sterol metabolites by GC-MS analysis
proved to be a valuable diagnostic tool, the absolute levels of 8-
DHC and cholestenol do not allow prediction of the type of
Figure 3. GC-MS results (A) GC-MS analysis of the mother of family 3. (B) GC-MS analysis of an unaffected control person. (A) and (B) show (a)
the total ion current, (b) the single ion monitoring for the ion m/z 351, and (c) the mass trace of the sum of the ions m/z 213 + 255 + 353. These
ions are speci®cally prominent in the mass spectra of 8-DHC and cholestenol, respectively, which accumulate in the serum of the affected probands.
Figure 4. Sequence analysis in the father of family 1. Mutant
sequence 440(G®A) (codon CGC changed to CAC) identi®ed in DNA
from hair follicles (a) and sperm (b) but not from lymphocytes (c). These
results demonstrate that this person has a somatic and gonadal mosaicism
for the 440(G®A) mutation.
1Sillevis Smitt JH, Jansweijer JWE: X-linked dominant chondrodysplasia
punctata in a boy. In 17th World Congress of Dermatology, Part II:502, 1987
(abstr.)
2Metzenberg AB, Kelley R, Smith D, Kopacz K., Suthpen R, Shef®eld
G, Herman G: Mutations in chondrodysplasia punctata, X-linked
dominant type. Am J Hum Genet, Suppl Oct, abstract 2729, 1999
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mutation and there was no obvious correlation with the clinical
phenotype. Thus the proband of family 1 is mildly affected showing
at birth only cutaneous signs, but has the highest levels of the two
cholesterol precursors in her serum. A second measurement 1 y
later showed a decrease but still this patient has higher values than
seen in some of the severely affected patients. In the meantime this
girl is 2 y of age and now has developed obvious kyphoscoliosis
(clinical score 4). The proband of family 4 and the mother of the
proband of family 11 both have the full spectrum of clinical ®ndings
of the CHH syndrome and are almost immobile in a wheel chair
(both, clinical score 7). They show different pro®les of cholesterol
precursor levels (8-DHC 6.5 and 2.4 mg per liter, respectively, and
cholestenol 12 and 3 mg per liter, respectively). The clinically
unaffected male gene carrier (family 1) (clinical score 0) has similar
Figure 5. Mutation analysis. (a) Family 3; (b)
family 4; (c) family 6; (d) family 7; (e) family 8; (f)
family 10.
Figure 6. Cholesterol biosynthesis pathway.
Enzymatic block caused by de®ciency of D8±D7
sterol isomerase leads to the accumulation of
8-DHC and cholestenol.
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levels (DHC 3.8 mg per liter and cholestenol 3.5 mg per liter) to
the proband of family 2 (DHC 3.0 mg per liter and cholestenol
2.7 mg per liter), who has a clinical score of 5. Also we had
expected that the frameshift mutation resulting in an early
termination of the synthesis would have a strong effect on the
serum sterol levels. It turned out that in the proband of family 2,
however, the biochemical abnormalities were comparatively mod-
erate. In contrast, missense mutations (family 1 and 3) had strong
biochemical consequences. We are aware that serum levels of the
cholesterol precursors re¯ect the metabolic situation of the liver and
further peripheral tissues and not of the bone and skin that were
used to score clinical severity. Nevertheless, similar considerations
apply for the SLO syndrome in which a correlation between serum
levels and disease severity has been found.
In the CHH syndrome these differences as well as phenotypic
differences in the same mutation are probably due to differences in
X-chromosome inactivation. It would be conceivable that D8±D7
sterol isomerase de®cient clones are outgrown by pro®cient clones,
resulting in an improvement of the biochemical defect after some
time. Such a loss of mutant lymphocyte clones has been recognized
in other X-linked disorders including X-linked agammaglobuline-
mia (Allen et al, 1994) and incontinentia pigmenti (Wieacker et al,
1985; Migeon et al, 1989). In the CHH syndrome loss of mutant
clone in the epidermis is very likely to underlie the change of
highly active disease at birth to almost inactive disease in later life,
characterized by follicular atrophoderma and small areas of
hyperkeratosis.
The formal pathogenesis of the CHH syndrome, i.e., the
question why patients develop for example asymmetric chondro-
dysplasia punctata, linear ichthyosis, and asymmetric cataracts is so
far not fully understood. In view of our ®ndings of the CHH
syndrome being a metabolic defect, there are a number of possible
explanations: (i) the clinical phenotype is caused by the toxic effect
of accumulated products, such as 8-DHC and cholestenol; (ii) the
lack of cholesterol and of cholesterol precursors at the individual
cell level plays a major role for further differentiation of these cells.
In the past it has been shown that drugs that interfere with
cholesterol biosynthesis and actually reduce cholesterol levels can
induce ichthyosis-like skin changes (Achor et al, 1961;
Winkelmann et al, 1963). In this context it should be noted that
the epidermis has its ``own'' cholesterol biosynthesis and is not
dependent on uptake of exogeneous sources (Melnik, 1989). A
target for such a role in differentiation may be the cholesterol
modi®cations of hedgehog proteins involved in cell signaling
(Porter et al, 1996; Lewis et al, 2001). We conclude that the CHH
syndrome is a metabolic defect and determination of sterol
metabolites by GC-MS analysis is a valuable tool in its diagnosis
and may even help to identify patients having somatic and gonadal
mosaicism. The extent of the biochemical alterations, however,
does not re¯ect the clinical phenotype, nor the genotype.
We want to thank the family members who participated in this study. This work
was supported by a grant from the self support group Ichthyosis e.V. to H.T. and by
a grant from the Deutsche Forschungsgemeinschaft (Tr 228/6-1).
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